KVA-12123 is under clinical development by Kineta and currently in Phase II for Transitional Cell Cancer (Urothelial Cell Cancer). According to GlobalData, Phase II drugs for Transitional Cell Cancer (Urothelial Cell Cancer) have a 25% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how KVA-12123’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

KVA-12123 overview

KVA-12123 is under development for the treatment of solid tumors including colorectal cancer (CRC), non-small cell lung cancer (NSCLC), ovarian cancer (OC), renal cell carcinoma, melanoma and head and neck cancer squamous cell carcinoma, bladder cancer, leiomyosarcoma, colon cancer, transitional cell cancer (urothelial cell cancer), pancreatic cancer. It acts by targeting v-region immunoglobulin-containing suppressor of T cell activation (VISTA). It is administered through intravenous route as infusion. It was also under development for acute myelocytic leukemia (AML). It is a fully human engineered IgG1 monoclonal antibody that was designed to bind to VISTA through a unique epitope. It was under development for the treatment of hepatocellular carcinomas, squamous cell carcinoma of the skin and cervical cancer.

Kineta overview

Kineta, formerly Yumanity Therapeutics Inc, is a clinical stage development company focused on the development of next-generation immunotherapies. Kineta has successfully established its Innate Immunity Development Platform with the purpose of creating fully human antibodies that target the key mechanisms responsible for cancer immune resistance. These mechanisms include immuno-suppression, exhausted T cells, and poor tumor immunogenicity. Its major pipeline products include KVA12123, Anti-CD27 agonist mAb immunotherapy and Anti-CD24 antagonistmAb immunotherapy. Kineta is headquartered in Seattle, Washington, the US.

For a complete picture of KVA-12123’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 7 February 2024

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.